/ 2 items

#BDTX↓

BDTX/ 12/03/2025 · 2:28 PM

Guggenheim Downgrades Black Diamond Therapeutics on Silevertinib Concerns

Guggenheim lowers Black Diamond Therapeutics to Neutral, citing toxicity and durability concerns in silevertinib’s Phase 2 trial and risks to key 2026 catalysts.

Variety of chemotherapy drugs in vials and an IV bottle.

SNDX/ 10/16/2025 · 10:25 AM

Wall Street Analysts Issue Buy Ratings on Five Cancer Treatment Companies

H.C. Wainwright, Stifel, and Cantor Fitzgerald issue Buy ratings on five biotech stocks including Syndax, Black Diamond, Revolution Medicines, Verastem, and Nuvalent, citing breakthrough cancer treatments.